Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 126-132 , March 2010

Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients

  • JoAnne M. Foody, MD, FACC, FAHA

      Affiliations

    • Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding Author:
    • ,
  • Shiva G. Sajjan, PhD

      Affiliations

    • Merck and Co, Inc., Whitehouse Station, NJ, USA
    • ,
  • X. Henry Hu, MD, PhD

      Affiliations

    • Merck and Co, Inc., Whitehouse Station, NJ, USA
    • ,
  • Dena R. Ramey, BA

      Affiliations

    • Merck and Co, Inc., N. Wales, PA, USA
    • ,
  • David R. Neff, DO

      Affiliations

    • Merck and Co, Inc., N. Wales, PA, USA
    • ,
  • Andrew M. Tershakovec, MD, MPH

      Affiliations

    • Merck and Co, Inc., N. Wales, PA, USA
    • ,
  • Joanne E. Tomassini, PhD

      Affiliations

    • Merck and Co, Inc., N. Wales, PA, USA
    • ,
  • Chuck Wentworth, BS

      Affiliations

    • Merck and Co, Inc., N. Wales, PA, USA
    • ,
  • Kaan Tunceli, PhD

      Affiliations

    • Merck and Co, Inc., Whitehouse Station, NJ, USA

Received 28 January 2010 ,Accepted 29 January 2010.

References 

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;105:3143–3421
  2. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–2372
  3. Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health. 2008;11:1061–1069
  4. Atar D, Carmena R, Clemmensen P, et al. Clinical review: impact of statin substitution policies on patient outcomes. Ann Med. 2009;41:242–256
  5. Aronow H, Hess G, Hill J, Kuznik A, Liu L. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Ther. 2009 Sep 15;[epub ahead of print] PMID: 19770794
  6. Steinberg BA, Bhatt DL, Mehta S, et al. Diabetes and metabolism—nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156:719–727
  7. Catapano AL. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin. 2009;25:431–447
  8. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34
  9. Griend JPV, Saseen JJ. Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. J Clin Lipid. 2009;3:195–200
  10. Cullen MW, Stein JH, Gangnon R, McBride PE, Keevil JG. National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. Am Heart J. 2008;156:284–291
  11. Devine J, Linton A, Mistry H, Mapier J, Trice S, Bacon T. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: A population-based study. Pharmacoepidemiol Drug Safety. 2009;18:891–899
  12. Nag SS, Pearson TA, Ma L, et al. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease. Am J Cardiol. 2005;95:862–864
  13. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13:776–783
  14. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156:112–119
  15. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–563
  16. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia—Data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation. 2007;115:1363–1370

PII: S1933-2874(10)00046-2

doi: 10.1016/j.jacl.2010.01.007

Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 126-132 , March 2010

Article Tools

* Image Usage & Resolution